Robert Oberlender

Biography

Oberlender attended the pharmacy school of Temple University in his hometown of Philadelphia, Pennsylvania, receiving a bachelor's degree, and worked for two years as a pharmacist. and his last publication with the group was in 1995, a period spanning more than 10years. His Ph.D. thesis, published in 1989, was on stereoselective actions of psychedelics, including the lysergamides LA-Aziridine and LA-3Cl-SB and the DOx drugs DOIB and DOSB, as well as on drug discrimination studies of entactogens, including MDA, MDMA, MBDB, and MDAI. The chemist publicly shared further details of the incident during an interview with psychedelic journalist Hamilton Morris in 2021, describing it as a cautionary tale of the risks of self-experimentation with little-known psychoactive drugs and the importance of careful dose escalation and of having a trip sitter. New River Pharmaceuticals was purchased by Shire in 2007. That same year, lisdexamfetamine was initially approved and introduced for medical use under the brand name Vyvanse in the United States. Following these events, Oberlender started working at Synthonics in Blackburg, Virginia and began developing metal-coordinated pharmaceutical drugs at the company.

Selected publications

Alt URL